alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States

              																								United States. Congress. Joint Economic Committee, 1956-					 and 	Eighty-Sixth Congress, 1959-1961.						"Study Paper Nos. 2 and 3 : Steel and the Postwar Inflation and An Analysis of the Inflation in Machinery Prices" in *Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States*			(November 6, 1959).						https://fraser.stlouisfed.org/title/1244/item/3636, accessed on September 25, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
# C_2014142EN.01001801.xml

| 12.5.2014 | EN | Official Journal of the European Union | C 142/18 |
| --- | --- | --- | --- |

12.5.2014

EN

Official Journal of the European Union

C 142/18

---

Request for a preliminary ruling from the Corte Suprema di Cassazione (Italy) lodged on 17 February 2014 — Agenzia delle Entrate v Nuova Invincibile

(Case C-82/14)

2014/C 142/25

Language of the case: Italian

Referring court

Referring court

Corte Suprema di Cassazione

Parties to the main proceedings

Parties to the main proceedings

Applicant: Agenzia delle Entrate

Applicant:

Defendant: Nuova Invincibile

Defendant:

Question referred

Question referred

[Is a measure such as the tax amnesty provided for in Article 9(17) of Law No 289/2002, which relates to periods in the distant past and is intended to provide some degree of compensation to persons affected by natural disasters], in so far as it has an effect on the total amounts received (or receivable) after the application of VAT, caught by the prohibition underlying the judgment of Court of Justice of the European Union of 17 July 2008 in Case C-132/06?

---
#### § 822.30 May I request exemption from the requirement to conduct postmarket surveillance?

You may request exemption from the requirement to conduct postmarket surveillance for your device or any specific model of that device at any time. You must comply with the requirements of this part unless and until we grant an exemption for your device. Your request for exemption must explain why you believe we should exempt the device or model from postmarket surveillance. You should demonstrate why the surveillance question does not apply to your device or does not need to be answered for the device for which you are requesting exemption. Alternatively, you may provide information that answers the surveillance question for your device, with supporting documentation, to the address in § 822.8.
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 02-7912
UNITED STATES OF AMERICA, Plaintiff - Appellee, versus LARRY KENNETH SPEED, a/k/a Kenny Speed, a/k/a Kenneth Richard Godfrey, Defendant - Appellant. Appeal from the United States District Court for the Eastern District of Virginia, at Norfolk. Raymond A. Jackson, District Judge. (CR-00-92, CA-02-230-2) Submitted: April 24, 2003 Decided: May 1, 2003 Before NIEMEYER, GREGORY, and SHEDD, Circuit Judges. Dismissed by unpublished per curiam opinion. Larry Kenneth Speed, Appellant Pro Se. Laura P. Tayman, OFFICE OF THE UNITED STATES ATTORNEY, Norfolk Virginia, for Appellee. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Larry Speed seeks to appeal the district court’s order denying his 28 U.S.C. § 2255 (2000) motion. An appeal may not be taken from the final order in a motion under § 2255 unless a circuit justice or judge issues a certificate of appealability. 28 U.S.C. § 2253(c)(1) (2000). A certificate of appealability will not issue for claims addressed by a district court on the merits absent “a substantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (2000). We have independently reviewed the record and conclude Speed has not made the requisite showing. See Miller-El v. Cockrell , U.S. , 123 S. Ct. 1029 (2003). Accordingly, we deny a certificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

DISMISSED
§ 812.27 Report of prior investigations. ( a ) *General.* The report of prior investigations shall include reports of all prior clinical, animal, and laboratory testing of the device and shall be comprehensive and adequate to justify the proposed investigation.
( b ) *Specific contents.* The report also shall include: ( 1 ) A bibliography of all publications, whether adverse or supportive, that are relevant to an evaluation of the safety or effectiveness of the device, copies of all published and unpublished adverse information, and, if requested by an IRB or FDA, copies of other significant publications.
( 2 ) A summary of all other unpublished information (whether adverse or supportive) in the possession of, or reasonably obtainable by, the sponsor that is relevant to an evaluation of the safety or effectiveness of the device.
( 3 ) If information on nonclinical laboratory studies is provided, a statement that all such studies have been conducted in compliance with applicable requirements in the good laboratory practice regulations in part 58, or if any such study was not conducted in compliance with such regulations, a brief statement of the reason for the noncompliance. Failure or inability to comply with this requirement does not justify failure to provide information on a relevant nonclinical test study.
( 4 ) ( i ) If data from clinical investigations conducted in the United States are provided, a statement that each investigation was conducted in compliance with applicable requirements in the protection of human subjects regulations in part 50 of this chapter, the institutional review boards regulations in part 56 of this chapter, or was not subject to the regulations under § 56.104 or § 56.105, and the investigational device exemptions regulations in this part, or if any such investigation was not conducted in compliance with those regulations, a brief statement of the reason for the noncompliance. Failure or inability to comply with these requirements does not justify failure to provide information on a relevant clinical investigation.
( ii ) If data from clinical investigations conducted outside the United States are provided to support the IDE, the requirements under § 812.28 apply. If any such investigation was not conducted in accordance with good clinical practice (GCP) as described in § 812.28(a), the report of prior investigations shall include either a waiver request in accordance with § 812.28(c) or a brief statement of the reason for not conducting the investigation in accordance with GCP and a description of steps taken to ensure that the data and results are credible and accurate and that the rights, safety, and well-being of subjects have been adequately protected. Failure or inability to comply with these requirements does not justify failure to provide information on a relevant clinical investigation.
[45 FR 3751, Jan. 18, 1980, as amended at 50 FR 7518, Feb. 22, 1985; 83 FR 7385, Feb. 21, 2018]
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                       1,974,629
<SECURITIES>                                         0
<RECEIVABLES>                                2,063,249
<ALLOWANCES>                                    60,000
<INVENTORY>                                  1,821,013
<CURRENT-ASSETS>                             8,197,385
<PP&E>                                       5,576,757
<DEPRECIATION>                               2,397,798
<TOTAL-ASSETS>                              28,041,595
<CURRENT-LIABILITIES>                        8,598,723
<BONDS>                                     19,672,049
<PREFERRED-MANDATORY>                       11,221,700
<PREFERRED>                                          4
<COMMON>                                           537
<OTHER-SE>                                 (9,306,689)
<TOTAL-LIABILITY-AND-EQUITY>                28,041,595
<SALES>                                     13,452,204
<TOTAL-REVENUES>                            13,452,204
<CGS>                                        9,493,058
<TOTAL-COSTS>                                9,493,058
<OTHER-EXPENSES>                             9,843,187
<LOSS-PROVISION>                                99,000
<INTEREST-EXPENSE>                           2,496,418
<INCOME-PRETAX>                            (8,479,459)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (8,479,459)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (8,479,459)
<EPS-PRIMARY>                                   (2.39)
<EPS-DILUTED>                                   (2.39)
        

</TABLE>
Exhibit 31.1

CERTIFICATION



I, Craig
H. Muhlhauser certify that:



1. I have
reviewed this quarterly report on Form 10-Q of Exide Technologies;



2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report;



3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;



4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:



(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being
prepared;



(b) Evaluated the effectiveness of
the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



(c) Disclosed in this report any change in
the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrants internal control over financial reporting; and



5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent function):



(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and



(b) Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrants internal controls over financial reporting.



Date: February 17, 2004



|    |  |                                                                    
|--- |  | -------------------------------------------------------------------
|    | 
|By: |  | /s/    CRAIG H. MUHLHAUSER                                         
|    |  |                                                                    
|    |  | Craig H. Muhlhauser Chairman, President and Chief Executive Officer
Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Thomas J. Shaw, certify that:

1. I have reviewed this annual report on Form 10-K of Retractable Technologies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my
knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods
presented in this report;

4. The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) for the registrant and have:

a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;

b) Evaluated the effectiveness of the registrants disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation;

c) Disclosed in this report any changes in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal
quarter (the registrants fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal controls over financial reporting; and

5. The registrants other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):

a) All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize, and report
financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the
registrants internal control over financial reporting.

Date: March 31, 2006



/s/ THOMAS J. SHAWTHOMAS J. SHAWPRESIDENT, CHAIRMAN, ANDCHIEF EXECUTIVE OFFICER
# C_2016106EN.01004701.xml

| 21.3.2016 | EN | Official Journal of the European Union | C 106/47 |
| --- | --- | --- | --- |

21.3.2016

EN

Official Journal of the European Union

C 106/47

---

Judgment of the Civil Service Tribunal (Third Chamber) of 5 February 2016 –Bulté and Krempa v Commission

(Case F-96/14) (1)

1

((Civil service - Surviving dependants of a deceased former official - Pensions - Survivors’ pensions - Article 85 of the Staff Regulations - Recovery of overpayment - No due reason for the payment - Patent irregularity - None))

(2016/C 106/56)

Language of the case: French

Parties

Parties

Applicants: Hilde Bulté and Tom Krempa (Brussels, Belgium) (represented by: J. Lombaert and A. Surny, lawyers)

Applicants:

Defendant: European Commission (represented initially by J. Currall and G. Gattinara, acting as Agents, and subsequently by G. Gattinara, acting as Agent)

Defendant:

Re:

Re:

Application for annulment of the decision taken by the Commission retroactively revising the survivors’ pensions paid to the applicants and ordering the recovery of the excess amounts received.

Operative part of the judgment

Operative part of the judgment

The Tribunal:

| 1. | Annuls the decision of the European Commission of 22 November 2013, as set out in the opinion of the Paymaster Office of the same day, to modify, with retroactive effect from 1 August 2010, the pensions paid to Ms Bulté and Mr Krempa in their capacity as the surviving dependants of a deceased former official and to recover the sums overpaid to them from 1 August 2010 until November 2013; |
| --- | --- |

1.

Annuls the decision of the European Commission of 22 November 2013, as set out in the opinion of the Paymaster Office of the same day, to modify, with retroactive effect from 1 August 2010, the pensions paid to Ms Bulté and Mr Krempa in their capacity as the surviving dependants of a deceased former official and to recover the sums overpaid to them from 1 August 2010 until November 2013;

| 2. | Orders the European Commission to reimburse Ms Bulté and Mr Krempa for the sums levied on their respective pensions pursuant to the decision referred to in paragraph 1 of this operative part; |
| --- | --- |

2.

Orders the European Commission to reimburse Ms Bulté and Mr Krempa for the sums levied on their respective pensions pursuant to the decision referred to in paragraph 1 of this operative part;

| 3. | Orders each of the parties to bear their own costs. |
| --- | --- |

3.

Orders each of the parties to bear their own costs.

---

(1)  OJ C 7, 12.1.2015, p. 49.

1

---
§ 522.163 Betamethasone dipropionate and betamethasone sodium phosphate aqueous suspension. ( a ) *Specifications.* Betamethasone dipropionate and betamethasone sodium phosphate aqueous suspension is a sterile aqueous suspension. Each milliliter of the suspension contains the equivalent of 5 milligrams of betamethasone as betamethasone dipropionate and 2 milligrams of betamethasone as betamethasone sodium phosphate.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Dogs.* ( i ) It is used as an aid in the control of pruritus associated with dermatoses.
( ii ) It is administered by intramuscular injection at a dosage of 0.25 to 0.5 milliliter per 20 pounds of body weight, depending on the severity of the condition. Frequency of dosage depends on recurrence of pruritic symptoms. Dosage may be repeated every 3 weeks or when symptoms recur, not to exceed a total of 4 injections.
( 2 ) *Horses.* ( i ) It is used as an aid in the control of inflammation associated with various arthropathies.
( ii ) It is administered aseptically by intraarticular injection at a dosage of 2.5 to 5 milliliters per joint, depending on the severity of the condition and the joint size. Dosage may be repeated upon recurrence of clinical signs. Injection into the joint cavity should be preceded by withdrawal of synovial fluid.
( iii ) Not for use in horses intended for food.
( 3 ) *Clinical and experimental data.* It has been demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.
( 4 ) *Restrictions.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13858, Mar. 27, 1975, as amended at 41 FR 27316, July 2, 1976; 52 FR 7832, Mar. 13, 1987]
Exhibit
31.2



CERTIFICATION



I,
Lance V. Schulz, certify that:



|1. | I
    have reviewed this Amendment No. 2 on Form 10-K/A to the annual report on Form 10-K for the year ended December 31, 2017 of
    Ballantyne Strong, Inc.; and                                                                                                                                                    
|-- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                       
|2. | Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report.



| | By: | /s/
    LANCE V. SCHULZ                                                                         
| | --- | ------------------------------------------------------------------------------------------------
| |     | Lance
                                         V. Schulz
        Chief
        Financial Officer



April
26, 2018